Binosto

Osteoporosis, Osteoporosis caused by glucocorticoid, Postmenopause + 2 more
Treatment
4 FDA approvals
20 Active Studies for Binosto

What is Binosto

Alendronic acidThe Generic name of this drug
Treatment SummaryAlendronic Acid is a medication used to treat certain types of osteoporosis and Paget's disease. It works by preventing the breakdown of bones and helps to keep them strong.
Fosamaxis the brand name
image of different drug pills on a surface
Binosto Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Fosamax
Alendronic acid
1996
86

Approved as Treatment by the FDA

Alendronic acid, also known as Fosamax, is approved by the FDA for 4 uses which include Paget’s Disease and Osteoporosis caused by glucocorticoid .
Paget’s Disease
Osteoporosis caused by glucocorticoid
Osteoporosis
Postmenopause

Effectiveness

How Binosto Affects PatientsAlendronic acid tablets are not absorbed very well when taken by mouth. Most of the drug is distributed into soft tissue and bone, and some is eliminated in the urine. Alendronic acid does not change when it is processed by the body.
How Binosto works in the bodyAlendronic acid works by binding to the bones in the body. This helps reduce acidity in the bones and stops osteoclasts, which are cells that break down bones, from being able to do their job. As a result, bones become stronger and more resilient. This is evidenced by lower urinary calcium, deoxypyridinoline, and N-telopeptidase levels.

When to interrupt dosage

The suggested measure of Binosto is reliant upon the diagnosed condition, such as Osteoporosis caused by glucocorticoid, Osteogenesis Imperfecta (OI) and Paget’s Disease. The dosage fluctuates, depending on the technique of delivery detailed in the table below.
Condition
Dosage
Administration
Osteoporosis
70.0 mg, 5.0 mg, 35.0 mg, 10.0 mg, 40.0 mg, , 7.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Tablet, effervescent, Tablet, effervescent - Oral
Osteogenesis Imperfecta (OI)
70.0 mg, 5.0 mg, 35.0 mg, 10.0 mg, 40.0 mg, , 7.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Tablet, effervescent, Tablet, effervescent - Oral
Postmenopause
70.0 mg, 5.0 mg, 35.0 mg, 10.0 mg, 40.0 mg, , 7.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Tablet, effervescent, Tablet, effervescent - Oral
Osteoporosis caused by glucocorticoid
70.0 mg, 5.0 mg, 35.0 mg, 10.0 mg, 40.0 mg, , 7.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Tablet, effervescent, Tablet, effervescent - Oral
Paget’s Disease
70.0 mg, 5.0 mg, 35.0 mg, 10.0 mg, 40.0 mg, , 7.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Solution, Solution - Oral, Tablet, effervescent, Tablet, effervescent - Oral

Warnings

Binosto has six contraindications, so it should not be consumed when one has the conditions shown in the following table.Binosto Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Alendronic Acid may interact with Pulse Frequency
Achalasia
Do Not Combine
Hypocalcemia
Do Not Combine
Aspiration
Do Not Combine
Esophagus
Do Not Combine
Inability to stand or sit upright for at least 30 minutes
Do Not Combine
There are 20 known major drug interactions with Binosto.
Common Binosto Drug Interactions
Drug Name
Risk Level
Description
Clodronic acid
Minor
The risk or severity of adverse effects can be increased when Alendronic acid is combined with Clodronic acid.
Etidronic acid
Minor
The risk or severity of adverse effects can be increased when Alendronic acid is combined with Etidronic acid.
Incadronic acid
Minor
The risk or severity of adverse effects can be increased when Alendronic acid is combined with Incadronic acid.
Tiludronic acid
Minor
The risk or severity of adverse effects can be increased when Alendronic acid is combined with Tiludronic acid.
Acipimox
Moderate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Acipimox.
Binosto Toxicity & Overdose RiskTaking alendronic acid may cause abdominal pain, heartburn, constipation, diarrhea, indigestion, muscle pain, and nausea in at least 3 out of 100 patients. If an overdose occurs, milk or antacids should be administered and vomiting should not be induced. Low calcium and phosphorus levels, as well as upper gastrointestinal events, may also occur. Studies of pregnant rats showed complications at four times the clinical dose, but pregnant rabbits did not show complications at up to ten times the clinical dose. Whether alendronic acid is safe for breastfeeding is unknown. There are no studies about its use in pediatric patients, though more
image of a doctor in a lab doing drug, clinical research

Binosto Novel Uses: Which Conditions Have a Clinical Trial Featuring Binosto?

50 active trials are presently underway to assess the effectiveness of Binosto in treating Osteogenesis Imperfecta (OI), Osteoporosis and Glucocorticoid-induced Osteoporosis.
Condition
Clinical Trials
Trial Phases
Osteoporosis caused by glucocorticoid
0 Actively Recruiting
Osteogenesis Imperfecta (OI)
0 Actively Recruiting
Paget’s Disease
0 Actively Recruiting
Osteoporosis
43 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4, Phase 3
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable

Binosto Reviews: What are patients saying about Binosto?

5Patient Review
11/19/2015
Binosto for Decreased Bone Mass Following Menopause
I just started this treatment, but I wanted to see if it worked for other people before continuing.
1Patient Review
7/30/2018
Binosto for Decreased Bone Mass Following Menopause
Unfortunately, this medication caused me so much pain in my bones and joints that I had to stop taking it.

Patient Q&A Section about binosto

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Binosto the same as Fosamax?

"The FDA approved BINOSTO as a bioequivalent to Fosamax1. BINOSTO is an effervescent tablet that dissolves in water to become a strawberry-flavored, buffered solution. The additional benefit is that BINOSTO does not need to be swallowed whole like a tablet."

Answered by AI

What is Binosto used for?

"Binosto is a prescription medicine used to:

  1. Treat thinning of your bones (osteoporosis) in women after menopause. Binosto helps reduce the chance of having a hip or spinal fracture (break).
  2. Increase bone mass in men who have osteoporosis."
Answered by AI

What does Binosto cost?

"Cost for the Binosto oral tablet, effervescent 70 mg, ranges from $325 to $345 for 4 tablets depending on the chosen pharmacy. The prices are only valid for cash paying customers and are not eligible with insurance plans."

Answered by AI

Is Binosto a bisphosphonate?

"Binosto (alendronate sodium) is a bisphosphonate used in the treatment of osteoporosis in postmenopausal women. It is also used in treatment to increase bone mass in men with osteoporosis."

Answered by AI

Clinical Trials for Binosto

Have you considered Binosto clinical trials? We made a collection of clinical trials featuring Binosto, we think they might fit your search criteria.
Have you considered Binosto clinical trials? We made a collection of clinical trials featuring Binosto, we think they might fit your search criteria.
Have you considered Binosto clinical trials? We made a collection of clinical trials featuring Binosto, we think they might fit your search criteria.